Risk factors and antibiotic therapy in P. aeruginosa community-acquired pneumonia

Respirology

Volumn 20, Issue 4, 2015, Pages 660-666

  Sibila, Oriol ^a,b,c   Laserna, Elena ^c,d   Maselli, Diego Jose ^c,e   Fernandez, Juan Felipe ^c,e   Mortensen, Eric M ^f,g   Anzueto, Antonio ^c,e   Waterer, Grant ^h,i   Restrepo, Marcos I ^c,e,j  

^a HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^b BIOMEDICAL RESEARCH INSTITUTE SANT PAU IIB SANT PAU   (Spain)

^c Hospital Comarcal de Mollet   (Spain)

^d UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^e SOUTH TEXAS VETERANS HEALTH CARE SYSTEM   (United States)

^f VERDICT   (United States)

^g VA NORTH TEXAS HEALTH CARE SYSTEM   (United States)

^h UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

ⁱ NORTHWESTERN UNIVERSITY   (United States)

^j UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

more..

Author keywords

antibiotic treatment; community acquired pneumonia; Pseudomonas aeruginosa; risk factor

Indexed keywords

AMIKACIN; ANTIBIOTIC AGENT; AZTREONAM; CEFEPIME; CEFTAZIDIME; CIPROFLOXACIN; GENTAMICIN; HYPERTENSIVE FACTOR; IMIPENEM; LEVOFLOXACIN; MEROPENEM; PIPERACILLIN; TOBRAMYCIN; ANTIINFECTIVE AGENT;

AGED; ANTIBIOTIC THERAPY; ARTICLE; ARTIFICIAL VENTILATION; CEREBROVASCULAR DISEASE; CHARLSON COMORBIDITY INDEX; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; COMMUNITY ACQUIRED PNEUMONIA; CONTROLLED STUDY; DEMENTIA; DIABETES MELLITUS; DISEASE DURATION; FEMALE; HEART FAILURE; HEART INFARCTION; HUMAN; ICD-9-CM; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; METASTASIS; MORTALITY; PERIPHERAL VASCULAR DISEASE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RETROSPECTIVE STUDY; RISK FACTOR; TREATMENT DURATION; CLINICAL TRIAL; COMMUNITY-ACQUIRED INFECTIONS; HEALTH SURVEY; INCIDENCE; ISOLATION AND PURIFICATION; MICROBIOLOGY; MULTICENTER STUDY; PNEUMONIA; PSEUDOMONAS INFECTIONS; UNITED STATES;

AGED; ANTI-BACTERIAL AGENTS; COMMUNITY-ACQUIRED INFECTIONS; FEMALE; HUMANS; INCIDENCE; MALE; PNEUMONIA; POPULATION SURVEILLANCE; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RETROSPECTIVE STUDIES; RISK FACTORS; UNITED STATES;

EID: 84927913342     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/resp.12506     Document Type: Article

References (32)

1. Kozak LJ, DeFrances CJ, Hall MJ,. National hospital discharge survey: 2004 annual summary with detailed diagnosis and procedure data. Vital Health Stat. 2006; 162: 1-209.
2. Trotter CL, Stuart JM, George R, Miller E,. Increasing hospital admissions for pneumonia, England. Emerg. Infect. Dis. 2008; 14: 727-733.
3. Restrepo MI, Anzueto A,. Severe community-acquired pneumonia. Infect. Dis. Clin. North. Am. 2009; 23: 503-520.
4. Woodhead M, Welch CA, Harrison DA, Bellingan G, Ayres JG,. Community-acquired pneumonia on the intensive care unit; secondary analysis of 17,869 cases in the ICNARC Case Mix Programme Database. Crit. Care 2006; 10 (Suppl. 2): S1.
5. Angus DC, Marrie TJ, Obrosky DS, Obrosky DS, Clermont G, Dremsizov TT, Coley C, Fine MJ, Singer DE, Kapoor WN,. Severe community-acquired pneumonia: use of intensive care services and evaluation of American and British Thoracic Society Diagnostic criteria. Am. J. Respir. Crit. Care Med. 2002; 166: 717-723.
6. Fujitani S, Sun HY, Yu VL, Weingarten JA,. Pneumonia due to Pseudomonas aeruginosa: part I: epidemiology, clinical diagnosis, and source. Chest 2011; 139: 909-919.
7. Arancibia F, Bauer TT, Ewig S, Mensa J, Gonzalez J, Niederman M, Torres A,. Community-acquired pneumonia due to gram-negative bacteria and pseudomonas aeruginosa: incidence, risk, and prognosis. Arch. Intern. Med. 2002; 162: 1849-1858.
8. Kang CI, Song JH, Oh WS, Ko KS, Chung DR, Peck KR, ANSORP Study Group. Clinical outcomes and risk factors of community-acquired pneumonia caused by gram-negative bacilli. Eur. J. Clin. Microbiol. Infect. Dis. 2008; 27: 657-661.
9. Falguera M, Carratalà J, Ruiz-Gonzalez A, Garcia-Vidal C, Gazquez I, Dorca J, Gudiol F, Porcel JM,. Risk factors and outcome of community-acquired pneumonia due to Gram-negative bacilli. Respirology 2009; 14: 105-111.
10. von Baum H, Welte T, Marre R, Suttorp N, Ewig S, CAPNETZ Study Group. Community-acquired pneumonia through Enterobacteriaceae and Pseudomonas aeruginosa: diagnosis, incidence and predictors. Eur. Respir. J. 2010; 35: 598-605.
11. Sibila O, Restrepo MI, Anzueto A,. What is the best antimicrobial treatment for severe community-acquired pneumonia (including role of steroids, statins and other immunomodulatory agents). Infect. Dis. Clin. North Am. 2013; 27: 133-147.
12. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, Dowell SF, File TM Jr, Musher DM, Niederman MS, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines for the management of community acquired pneumonia in adults. Clin. Infect. Dis. 2007; 44: S27-72.
13. Niederman MS, Craven DE, Bonten MJ, Chastre J, Craig WA, Fagon JY, Hall J, Jacoby GA, Kollef MH, Luna CM, et al. Guidelines for the management of adults with hospital-acquired pneumonia, ventilator-associated pneumonia and healthcare-associated pneumonia. Am. J. Respir. Crit. Care Med. 2005; 171: 338-416.
14. Attridge RT, Frei CR, Restrepo MI, Lawson KA, Ryan L, Pugh MJ, Anzueto A, Mortensen EM,. Guideline-concordant therapy and outcomes in healthcare-associated pneumonia. Eur. Respir. J. 2011; 38: 878-887.
15. Fang GD, Fine M, Orloff J, Arisumi D, Yu VL, Kapoor W, Grayston JT, Wang SP, Kohler R, Muder RR,. New and emerging etiologies for community-acquired pneumonia with implications for therapy. A prospective multicenter of 359 cases. Medicine (Baltimore) 1990; 60: 307-316.
16. Neill AM, Martin IR, Weir R, Anderson R, Chereshsky A, Epton MJ, Jackson R, Schousboe M, Frampton C, Hutton S, et al. Community acquired pneumonia: aetiology and usefulness of severity criteria on admission. Thorax 1996; 51: 1010-1016.
17. Dambrava PG, Torres A, Valles X, Mensa J, Marcos MA, Peñarroja G, Camps M, Estruch R, Sanchez M, Menendez R, et al. Adherence to guidelines' empirical treatment and community-acquired pneumonia outcome. Eur. Respir. J. 2008; 32: 892-901.
18. Fine MJ, Smith MA, Carson CA, Mutha SS, Sankey SS, Weissfeld LA, Kapoor WN,. Prognosis and outcomes of patients with community-acquired pneumonia. A meta-analysis. JAMA 1996; 275: 134-141.
19. Patel IS, Seemungal TA, Wilks M, Lloyd-Owen SJ, Donaldson GC, Wedzicha JA,. Relationship between bacterial colonization and the frequency, character, and severity of COPD exacerbations. Thorax 2002; 57: 759-764.
20. Papi A, Belletato CM, Braccioni F, Romagnoli M, Casolari P, Caramori G, Fabbri LM, Johnston SL,. Infection and airway inflammation in chronic obstructive pulmonary disease severe exacerbations. Am. J. Respir. Crit. Care Med. 2006; 173: 1114-1121.
21. Liapikou A, Polverino E, Ewig S, Cillõniz C, Marcos MA, Mensa J, Bello S, Martin-Loeches I, Menéndez R, Torres A,. Severity and outcomes of hospitalized community-acquired pneumonia in COPD patients. Eur. Respir. J. 2012; 39: 855-861.
22. Sethi S, Murphy TF,. Infection in the pathogenesis and course of chronic obstructive pulmonary disease. N. Engl. J. Med. 2008; 359: 2355-2365.
23. Murphy TF, Brauer AL, Eschberger K, Lobbins P, Grove L, Cai X, Sethi S,. Pseudomonas aeruginosa in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2008; 177: 853-860.
24. Restrepo MI, Aliberti S,. Healthcare-associated pneumonia: where do we go next? Clin. Infect. Dis. 2014; 58: 340-341.
25. Ewig S,. HCAP not busy being born is busy dying. Am. J. Respir. Crit. Care Med. 2014; 189: 365-366.
26. Chalmers JD, Rother C, Salih W, Ewig S,. Healthcare-associated pneumonia does not accurately identify potentially resistant pathogens: a systematic review and meta-analysis. Clin. Infect. Dis. 2014; 58: 330-339.
27. Garnacho-Montero J, Sa-Borges M, Sole-Violan J, Barcenilla F, Escoresca-Ortega A, Ochoa M, Cayuela A, Rello J,. Optimal management therapy for Pseudomonas aeruginosa ventilator-associated pneumonia: an observational, multicenter study comparing monotherapy with combination antibiotic therapy. Crit. Care Med. 2007; 35: 1888-1895.
28. Mueller EW, Hanes SD, Croce MA, Wood GC, Boucher BA, Fabian TC,. Effect from multiple episodes of inadequate empiric antibiotic therapy for ventilator-associated pneumonia on morbidity and mortality among critically ill trauma patients. J. Trauma 2005; 58: 94-101.
29. Leroy O, Meybeck A, d'Escrivan T, Devos P, Kipnis E, Georges H,. Impact of adequacy of initial antimicrobial therapy on the prognosis of patients with ventilator-associated pneumonia. Intensive Care Med. 2003; 29: 179-188.
30. Dupont H, Mentec H, Sollet JP, Bleichner G,. Mortality rate attributable to ventilator-associated nosocomial pneumonia in an adult intensive care unit: a prospective case-control study. Crit. Care Med. 2001; 29: 2303-2309.
31. Luna CM, Vujacich P, Niederman MS, Vay C, Gherardi C, Matera J, Jolly EC,. Impact of BAL data on therapy and outcome of ventilator-associated pneumonia. Chest 1997; 111: 676-685.
32. Aronsky D, Haug PJ, Lagor C, Dean NC,. Accuracy of administrative data for identifying patients with pneumonia. Am. J. Med. Qual. 2005; 20: 319-328.